|
Life Therapeutics Signs New Two Year Contract Valued up to A$12M per year
Sydney, Oct 24, 2006 (ABN Newswire) - Life Therapeutics (ASX: LFE)(PNK: LFEFY) has signed a new two year contract to produce hyperimmune plasma for a major fractionator. The value of the contract ranges from a minimum of A$4M up to A$12M per year for two years.
"This contract signals our further shift to producing the high-margin, hyperimmune plasma, which will further enhance our product mix," said Dr. Hari Nair, CEO and President of Life Therapeutics. "These types of high-margin products are what our company excels in producing and what our entire production system is geared to accomplish."
As previously advised, Life Therapeutics recently installed a new donor computer system company-wide to increase processing and aid production of hyperimmune and normal source plasma. This will further reduce the cost of product management and improve the order fulfilment process.
About LIFE THERAPEUTICS LIMITED
Life Therapeutics is an international company that specializes in niche therapeutic hyperimmune products. It has 14 operational plasma collection centers and signed leases for a further 2 centers around the US. The Company has considerable experience recruiting and collecting hard to find hyperimmune plasma for IND studies and clinical trials. Life Therapeutics has 500 employees, located in the United States and 14 plasma donor centers in eight American States. It has an established U.S. American Depositary Receipt (ADR) Level I program, which enables trading in Life Therapeutics shares by U.S. based investors. The company's divisions are all headquartered in Atlanta, Georgia.
|
|
|
